Found 834 articles
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023.
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
Homology Medicines, Inc., a genetic medicines company, announced enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria and the juMPStart Phase 1 gene therapy trial with HMI-203 for Hunter syndrome.
Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST in San Francisco, CA.
KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.
FDA Warns Seven Companies for Selling Dietary Supplements with Claims to Treat Cardiovascular Disease
Today, the U.S. Food and Drug Administration issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Juniper Research: Precision Medicine Spend to Exceed $132 Billion Globally by 2027; Driven by Efficiency Gains for Healthcare Providers
A new study from Juniper Research found that the total spend on precision medicine will reach $132.3 billion globally by 2027; increasing from only $35.7 billion in 2022.
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the third quarter ended September 30, 2022.
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the third quarter ended September 30, 2022.
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
Cara Therapeutics, Inc. announced that members of its Executive Leadership Team will present at the following investor conferences.
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time gene editing candidate HMI-103 in adults with phenylketonuria (PKU).
Terns Pharmaceuticals, Inc. announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, in clinical development for the treatment of NASH at the American Association for the Study of Liver Diseases The Liver Meeting®, which will be held November 4-8, 2022.
Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.
Education Resources, Inc. Announces 23rd Annual Therapies in the School Conference A Live Virtual Webinar - November 17 and 18, 2022
Education Resources, Inc. (ERI) announces the 23rd Annual Therapies in the School Conference, a live virtual webinar set for November 17 and 18, 2022 at 9:30 am EST (US).
Homology Medicines, Inc., a clinical-stage genetic medicines company, announced participation at the following conferences.
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP).
Homology Medicines, Inc., a genetic medicines company, announced the promotion of Albert Seymour, Ph.D., to Chief Executive Officer, President and member of the Board of Directors.
Cara Therapeutics, Inc. today announced the Company will host a virtual event focused on notalgia paresthetica (NP) on Tuesday, September 20, 2022, from 11:00 a.m. to 12:15 p.m. ET.